Hormone Health, Metabolism, and Prostate Wellness
Abstract
In this educational post, I take you through a practical, clinician-tested roadmap to understanding and treating hormone-related metabolic dysfunctions across the lifespan—particularly the interplay among sex hormone–binding globulin (SHBG), insulin resistance, polycystic ovary syndrome (PCOS), DHEA dynamics, and prostate-specific antigen (PSA) decision-making for men’s health. Drawing on current research and my clinical observations at Chiromed and in integrative practice, I explain why SHBG is not your enemy, how gut-driven insulin resistance amplifies androgen effects, how to identify PCOS phenotypes that do not look “typical,” and how to merge modern therapeutics (GLP-1s, metformin, spironolactone) with lifestyle, nutrition, and integrative chiropractic care to restore function. I also walk through PSA interpretation using percent free PSA and velocity, and when to order a 3T multiparametric prostate MRI. You will find physiologic context, step-by-step reasoning, and practical protocols you can apply immediately.
Key topics that follow
- SHBG physiology, clinical meaning, and why chasing a lower SHBG is usually counterproductive
- Insulin resistance, the gut–ovary axis, and PCOS phenotypes and treatment logic
- Practical dosing pearls for metformin, GLP-1 receptor agonists, and spironolactone
- DHEA physiology, neurological roles, and targeted use in men and women
- PSA, percent free PSA, velocity, and the role of 3T multiparametric MRI
- Where integrative chiropractic, movement therapy, and neuromusculoskeletal care fit into endocrine-metabolic care plans
Understanding SHBG, Free Testosterone, and Metabolic Health
I often meet patients who are symptomatic for low testosterone despite “normal” total testosterone. The missing piece is frequently sex hormone–binding globulin (SHBG)—a carrier protein synthesized in the liver that binds androgens (with a higher affinity for testosterone than for estradiol) and regulates the amount of hormone that is free and bioavailable to occupy intracellular receptors.
Core physiology, clearly explained
- SHBG binds circulating androgens. Bound hormone is transport-ready but not freely available to cross the cell membrane and activate intracellular androgen receptors.
- The fraction that remains free (or loosely albumin-bound) is bioavailable and exerts physiologic effects in target tissues (muscle, brain, bone, skin, reproductive organs).
- Hepatic SHBG synthesis is modulated by insulin, estrogen, and thyroid status. Hyperinsulinemia suppresses SHBG; estrogen and thyroid hormone tend to raise it.
- Clinically, a low SHBG often signals insulin resistance, while a higher SHBG is frequently associated with favorable metabolic profiles.
Why this matters clinically
- Patients with low SHBG often present with features of metabolic syndrome—even when A1c still looks “fine.” Multiple cohorts show that low SHBG is a predictive marker for insulin resistance, dysglycemia, and cardiometabolic risk in both women and men (Ding et al., 2009; Selva et al., 2007).
- Chasing a lower SHBG to “free up” testosterone usually misses the root cause and may worsen risk. Raising insulin (e.g., by overeating refined carbohydrates) can drop SHBG, but at a clear metabolic cost.
Evidence snapshot
- Prospective data indicate that low SHBG predicts incident type 2 diabetes in women and men independent of BMI and baseline glucose (Ding et al., 2009).
- Mechanistically, hepatic insulin signaling downregulates SHBG gene expression (Selva et al., 2007), providing a direct pathway from insulin resistance to low SHBG.
Treatment logic you can trust
- Goal: Improve insulin sensitivity and the liver’s metabolic set point rather than artificially forcing SHBG down.
- When symptomatic hypogonadism coexists with low SHBG, you may need to “saturate” androgen receptors by optimizing total testosterone so that the available free fraction reaches clinical effectiveness. The parallel, long-term fix is to address metabolic drivers that normalize SHBG.
Integrative chiropractic fit
- In our practice, optimized movement patterns, resistance training, and autonomic balance through chiropractic care and neuromusculoskeletal rehabilitation improve insulin sensitivity, lower systemic inflammation, and support hepatic health—mechanisms that indirectly help normalize SHBG. I find that restoring spinal mechanics and reducing pain enables patients to engage in consistent physical activity, a cornerstone for improving insulin signaling (see my practice observations at Chiromed).
PCOS, Insulin Resistance, and the Gut–Ovary Axis
PCOS is one of the most common endocrine disorders in women of reproductive age. Yet, it is easy to miss because many patients lack the classic triad of obesity, acne, and hirsutism. I routinely see athletic women with irregular cycles, dysmenorrhea, or infertility—sometimes the only obvious clue—who nonetheless have the hormonal signature of PCOS.
Current diagnostic framework
- Rotterdam criteria: Diagnose PCOS when at least 2 of 3 are present:
- Oligo- or anovulation (e.g., irregular or skipped cycles)
- Clinical/biochemical hyperandrogenism (e.g., hirsutism, acne, elevated free testosterone)
- Polycystic ovarian morphology (PCOM) on ultrasound
- Note: Not all patients have ovarian cysts, and total testosterone may be normal while free testosterone is elevated due to low SHBG.
Useful lab patterns
- Elevated LH: FSH ratio (often >2:1) in some premenopausal patients.
- Low or low-normal SHBG, elevated free testosterone; often high DHEA-S in adrenal-dominant phenotypes.
- Early insulin abnormalities and low SHBG can precede changes in A1c.
Why insulin resistance drives PCOS
- Hyperinsulinemia stimulates theca cells in the ovary to increase androgen production while simultaneously suppressing hepatic SHBG synthesis, thereby increasing free androgens (Escobar-Morreale, 2018).
- Gut dysbiosis and endotoxemia (LPS exposure) promote low-grade inflammation and worsen insulin signaling, propagating ovarian dysfunction (Zhang et al., 2019).
Atypical PCOS phenotypes I see
- Lean, athletic women with:
- Severe dysmenorrhea or irregular cycles
- Elevated LH: FSH
- High free T with normal total T
- High DHEA-S
- Minimal or no hirsutism/acne
This pattern demands a gut–metabolic workup even when body composition appears healthy. I frequently include stool microbiome testing when symptoms suggest dysbiosis.
Evidence-Based Treatment Algorithms for PCOS
My approach integrates metabolic therapy, targeted pharmacology, nutrition, and neuromusculoskeletal care.
- Normalize insulin signaling
- Metformin: Start low (e.g., 500 mg nightly) and titrate slowly to 1,500–2,000+ mg/day as tolerated to reduce hepatic gluconeogenesis and improve insulin sensitivity. GI side effects often attenuate with gradual titration and extended-release forms (Rena et al., 2017).
- GLP-1 receptor agonists (e.g., semaglutide, exenatide): Improve glucose-dependent insulin secretion, delay gastric emptying, reduce appetite, and facilitate weight loss; randomized trials show improved metabolic and reproductive outcomes in PCOS (Kahal et al., 2021; Elkind-Hirsch et al., 2008).
- Mechanistic payoff: Lower insulin raises SHBG and reduces androgenic “noise,” restoring ovulatory signaling.
- Manage androgenic symptoms while root-cause care takes hold
- Spironolactone: An aldosterone antagonist with androgen receptor–blocking activity; effective for hirsutism, acne. Typical doses 50–100 mg/day; allow 6–12 months for maximal effect (Brown et al., 2009).
- Combined oral contraceptives (COCs) with antiandrogenic progestins (e.g., drospirenone-containing formulations) can raise SHBG and reduce free T; useful for cycle control and symptom relief when pregnancy is not desired (Teede et al., 2018).
- Caution: Symptom control does not correct the insulin–ovary axis; keep metabolic therapy central.
- Nutrition, gut health, and inflammation
- Anti-inflammatory, Mediterranean-style diet with adequate protein, fiber, and omega-3 fatty acids improves insulin sensitivity and reduces ovarian androgen production (Barrea et al., 2019).
- Intermittent fasting (time-restricted eating) may improve insulin sensitivity and weight in appropriately selected patients; ensure adequate caloric intake and avoid in those with disordered eating tendencies (Patterson & Sears, 2017).
- Microbiome support: Address dysbiosis, SIBO, and intestinal permeability where indicated; diet, prebiotic fiber, and evidence-based probiotics can improve metabolic parameters.
- Movement and integrative chiropractic
- Consistent resistance training and aerobic exercise improve GLUT4 translocation, mitochondrial function, and insulin sensitivity. In my clinic, we pair individualized spinal and joint care with corrective exercise to reduce pain-related movement avoidance and enhance adherence.
- Autonomic balance matters: Many PCOS patients show sympathetic dominance; hands-on care and breathing-based neuromuscular retraining can reduce allostatic load and support ovulatory recovery.
- Fertility trajectory
- Expect cycles and ovulation to normalize over months to years as insulin sensitivity improves. I have seen patients regain regular ovulation and conceive after systematic, sustained metabolic and gut care—even in those previously considered “lean and healthy.”
Clinical pearls and cautions
- Start androgen therapy cautiously in PCOS or insulin-resistant women with low SHBG. Given the higher free fraction, standard doses can overshoot, increasing the risk of side effects. Start low and titrate slowly if testosterone therapy is clinically indicated for other reasons.
- Obtain LH and androgen panels in premenopausal patients with menstrual complaints or infertility—even if phenotype is nonclassic.
- Consider GI testing (e.g., stool analysis) when symptoms or history suggest dysbiosis, IBS, or food-triggered inflammation.
SHBG: What to Avoid and What to Embrace
Common misconception
- “Lower SHBG to increase free T.” This treats the lab number, not the disease process.
What to avoid
- Strategies that raise insulin (e.g., high refined carbohydrate load) just to lower SHBG.
- Unnecessary suppression of SHBG may worsen cardiometabolic risk.
What to embrace
- Improve insulin sensitivity through nutrition, exercise, sleep optimization, stress modulation, and gut care.
- Use medications like metformin and GLP-1 receptor agonists to shift the metabolic field when lifestyle alone is insufficient.
In my practice, when we prioritize insulin sensitivity and inflammation control, SHBG trends upward into healthier ranges, free testosterone normalizes relative to total testosterone, and symptoms improve without chasing lab artifacts.
PSA, Percent Free PSA, and Prostate MRI: Smarter Men’s Health
PSA screening has evolved. A single total PSA value is an imperfect signal. Two tools improve decision-making:
- Percent free PSA (%fPSA): The fraction of PSA not bound to serum proteins. Lower %fPSA indicates a higher likelihood of malignancy at a given total PSA.
- PSA velocity: The year-over-year change in PSA. Faster rises suggest higher risk.
How I interpret PSA in practice
- If total PSA is elevated (e.g., >4.0 ng/mL), I obtain percent free PSA. General rules supported by meta-analyses:
- %fPSA <10% = higher probability of prostate cancer
- %fPSA 10–20% = intermediate zone; consider prostatitis treatment if symptomatic and retest in ~3 months
- %fPSA >20% = lower probability; continue surveillance
- Consider PSA velocity: An increase >0.35–2.0 ng/mL/year—context-dependent—merits further evaluation even if the absolute PSA is “within range” (Vickers et al., 2011).
- Many benign factors elevate total PSA—intercourse, cycling, digital stimulation, BPH, prostatitis—but they do not significantly affect %fPSA, which is why I lean on percent free PSA for triage.
Imaging that changes outcomes
- If risk remains concerning (low %fPSA, rapid velocity, suspicious DRE, or persistent PSA elevation), I order a 3 Tesla multiparametric prostate MRI (mpMRI). This modality improves lesion detection and helps target biopsies, reducing unnecessary procedures (Ahmed et al., 2017).
- Most patients prefer an MRI over immediate biopsy, and mpMRI adds diagnostic clarity, including detection of chronic or acute prostatitis—a common cause of PSA bumps that I diagnose frequently.
Practical pearls
- Finasteride lowers total PSA by roughly ~50% but does not meaningfully change %fPSA—interpretation should be adjusted accordingly.
- Counsel patients to avoid prostate stimulation (e.g., ejaculation, vigorous cycling) for 48–72 hours before PSA sampling to reduce noise in total PSA.
- If PSA and %fPSA suggest low risk, recheck in 3 months rather than rushing to biopsy.
Testosterone therapy timing
- When PSA and urologic evaluation are reassuring, testosterone therapy can proceed with routine monitoring. I coordinate closely with urology, recognizing that practice styles vary.
DHEA Physiology, Brain Receptors, and When to Treat
Dehydroepiandrosterone (DHEA) and its sulfated form, DHEA-S, are produced primarily by the adrenal cortex and function as both endocrine prohormones and neurosteroids, with receptors and actions in the brain. Levels peak in the 20s and decline steadily with age. In both sexes, suboptimal DHEA can present as low vitality, depressed mood, impaired stress tolerance, and reduced sexual function—even when testosterone looks “good.”
Why DHEA matters
- Neurosteroid action: DHEA modulates GABAergic and glutamatergic tone, supporting mood, cognition, and arousal (Maninger et al., 2009).
- Peripheral conversion: DHEA can be converted to androgens and estrogens via tissue-specific enzymes; in women, a portion is converted to DHT in peripheral tissues, contributing to libido and sexual response.
- Immunometabolic effects: DHEA has anti-inflammatory properties and may influence endothelial function and bone metabolism.
Clinical patterns I see
- Women with adequate total and free testosterone who remain symptomatic for low libido or anorgasmia sometimes have low DHEA-S in the double digits. Carefully titrated DHEA supplementation often improves sexual function and overall well-being.
- In men and women with persistent fatigue and low mood despite thyroid/hormone optimization, DHEA can be the missing link.
Dosing logic
- I typically optimize thyroid and sex hormones first; DHEA often rises when metabolic stress decreases.
- If DHEA-S remains suboptimal:
- Women: 5–10 mg/day compounded DHEA; reassess at ~6 weeks
- Men: 20 mg/day compounded DHEA; reassess at ~6 weeks
- Over-the-counter options vary in potency; when used, I start around 25 mg/day with close follow-up.
- Monitor for androgenic side effects, especially in PCOS (who often already have high DHEA-S); avoid in hyperandrogenic phenotypes.
Evidence notes
- Studies link low DHEA-S to reduced well-being, depression, and sexual dysfunction, with improvements seen in targeted supplementation cohorts (Arlt et al., 1999; Wierman et al., 2014). Age-associated decline is robust and correlates with multiple health outcomes.
Why Integrative Chiropractic Care Belongs in Endocrine-Metabolic Programs
The neuromusculoskeletal system interfaces with the endocrine and immune systems through shared inflammatory and autonomic pathways. Here is how integrative chiropractic care fits, based on observations from my clinic and the scientific literature:
Mechanistic bridges
- Inflammation: Chronic pain amplifies IL-6 and TNF-α signaling, worsening insulin resistance. By reducing nociceptive drive and improving joint mechanics, manual therapies can lower inflammatory load and facilitate activity.
- Autonomic balance: Spinal and rib mechanics influence sympathetic/parasympathetic tone. Improved thoracic mobility and diaphragmatic function promote vagal activity, which supports glycemic control and gut motility—both key to the gut–ovary axis.
- Movement competency: Targeted strength and mobility programs enhance GLUT4 activity in skeletal muscle, thereby improving insulin sensitivity and supporting healthy SHBG levels.
In practice at Chiromed
- We build individualized plans that synchronize:
- Spinal and extremity joint care to enable pain-free training
- Progressive resistance training emphasizing posterior chain and hip mechanics
- Aerobic conditioning at sustainable intensities
- Breathing retraining and sleep hygiene to normalize cortisol rhythms
- This approach improves adherence to metabolic prescriptions, enabling the nutrition and pharmacology to “land” in real life.
Search-optimized section title Practical Protocols and Case-Style Reasoning
Putting it all together, here is how I apply the logic in daily care.
When SHBG is low, and symptoms suggest androgen deficiency
- Evaluate metabolic health: fasting insulin, lipids, liver enzymes, hs-CRP, A1c.
- Address insulin resistance first-line with nutrition, exercise, sleep, and stress management; consider metformin and/or GLP-1 RAs.
- If symptoms persist, carefully optimize testosterone with awareness that low SHBG increases free fraction—start low, titrate to symptom relief and physiologic targets.
When PCOS is likely, but the phenotype is atypical
- Order LH, FSH, total and free T, SHBG, DHEA-S, fasting insulin/glucose, and consider stool testing.
- Begin metabolic therapy plus symptom-directed therapy (spironolactone or COCs if appropriate and pregnancy not desired).
- Integrate resistance training and chiropractic-guided movement plans to accelerate insulin sensitivity and ovulatory recovery.
When initiating or adjusting DHEA
- Confirm suboptimal DHEA-S and symptom alignment (low mood, libido, vitality).
- Start low, reassess in 6–8 weeks, and monitor for androgenic side effects.
- Avoid in hyperandrogenic PCOS unless clearly indicated and monitored.
When PSA is elevated or changing fast
- Obtain percent free PSA and calculate velocity.
- If %fPSA <10% or velocity is concerning, proceed to 3T mpMRI; if prostatitis is suspected, treat and retest.
- Collaborate with urology based on mpMRI and clinical findings; delay testosterone changes until evaluation clarifies risk.
Why We Use Each Technique: The Physiology Behind the Protocols
- Metformin: Reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity via AMPK activation; lowers insulin, allowing SHBG to normalize and free T to calm down.
- GLP-1 receptor agonists: Enhance glucose-dependent insulin secretion, reduce appetite, and reduce systemic inflammation; improved ovulatory function reported in PCOS.
- Spironolactone: Direct androgen receptor blockade plus inhibition of 5α-reductase at higher doses; symptom relief while metabolic causes are corrected.
- DHEA: Restores neurosteroid tone and supports sexual function with selective peripheral conversion; used when clinically and biochemically indicated.
- Integrative chiropractic and movement: Improves neuromechanics and reduces pain, enabling training volume and intensity that improve insulin sensitivity; enhances autonomic balance affecting gut and endocrine axes.
Final Takeaways for Patients and Providers
- Think metabolically first: Low SHBG is often a metabolic distress signal, not a target to suppress.
- PCOS can be lean and subtle: Free T, LH: FSH, and DHEA-S mapping, plus gut assessment, can catch atypical cases.
- Combine symptom control and root-cause therapy: Use spironolactone or COCs for hirsutism/acne while you restore insulin sensitivity and gut health.
- Use smarter PSA strategies: Percent free PSA and PSA velocity reduce unnecessary biopsies and guide timely imaging with 3T mpMRI.
- Integrate care: When manual therapy, structured exercise, and metabolic medicine are aligned, recovery timelines shorten and outcomes improve.
References
Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., … Emberton, M. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, 389(10071), 815–822.
Arlt, W., Callies, F., van Vlijmen, J. C. M., Koehler, I., Reincke, M., Bidlingmaier, M., … Allolio, B. (1999). Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine, 341(14), 1013–1020.
Barrea, L., Marzullo, P., Muscogiuri, G., Di Somma, C., De Alteriis, G., Colao, A., & Savastano, S. (2019). Nutritional aspects of PCOS: an update. Advances in Nutrition, 10(2), 270–292.
Brown, J., Farquhar, C., Lee, O., Toomath, R., & Jepson, R. (2009). Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systematic Reviews, (2), CD000194.
Ding, E. L., Song, Y., Manson, J. E., Hunter, D. J., Lee, C.-C., Rifai, N., … Liu, S. (2009). Sex hormone–binding globulin and risk of type 2 diabetes in women and men. JAMA, 301(17), 1777–1786.
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008). Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in obese polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 93(7), 2670–2678.
Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Human Reproduction Update, 24(6), 671–698.
Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., & Kilpatrick, E. S. (2021). The effect of GLP-1 receptor agonists on cardiovascular risk factors in women with PCOS. Endocrine, 71, 199–206.
Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009). Neurobiological and neuropsychiatric effects of DHEA and DHEA-S. Psychoneuroendocrinology, 34(3), 273–286.
Patterson, R. E., & Sears, D. D. (2017). Metabolic effects of intermittent fasting. Annual Review of Nutrition, 37, 371–393.
Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. Nature Reviews Molecular Cell Biology, 19(1), 31–44.
Selva, D. M., Hogeveen, K. N., Innis, S. M., & Hammond, G. L. (2007). Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone–binding globulin gene. Journal of Clinical Investigation, 117(12), 3979–3987.
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., … International PCOS Network. (2018). Recommendations from the international evidence-based guideline for the assessment and management of PCOS. Human Reproduction, 33(9), 1602–1618.
Vickers, A. J., Savage, C., O’Brien, M. F., Lilja, H. (2011). Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. Journal of Clinical Oncology, 29(33), 447–453.
